Clinical stage/Groups | Frequency (FD)aand level of mRNA decrease (LDav)b | ||||||
---|---|---|---|---|---|---|---|
 |  | RBSP3 (59 tumors) | NPRL2 (59 tumors) | RASSF1A (36 tumors) | |||
 |  | AC | SCC | AC | SCC | AC | SCC |
I | FD LDav | *71 (5/7) *3 (2 -- 6) | *100 (11/11) *7 (2 -- 23) | 14 (1/7) 2 | *100 (11/11) *7 (2 -- 100) | 29 (2/7) 4 (3 -- 5) | 33 (2/6) 4 (2 -- 8) |
II | FD LDav | *60 (3/5) *5 (2 -- 9) | *79 (15/19) *4 (2 -- 11) | 40 (2/5) 6 (5--7) | *74 (14/19) *9 (2 -- 100) | 100 (1/1) 6 | 80 (4/5) 5 (2 -- 8) |
III | FD LDav | *100 (6/6) *6 (2 -- 26) | *91 (10/11) *8 (2 -- 94) | *83 (5/6) *4 (2 -- 7) | *91 (10/11) *10 (2 -- 100) | *100 (6/6) *7 (3 -- 21) | *82 (9/11) *7 (2 -- 57) |
Group without metastasis | FD LDav | *70 (7/10) *3 (2 -- 6) | *88 (21/24) *5 (2 -- 23) | *20 (2/10) *4 (2 -- 7) | *88 (21/24) *10 (2 -- 100) | 29 (2/7) 4 (3 -- 6) | 33 (2/6) 4 (2 -- 8) |
Group with metastasis | FD LDav | *88 (7/8) *6 (2 -- 26) | *88 (15/17) *7 (2 -- 94) | *75 (6/8) *4 (2 -- 7) | *82 (14/17) *8 (2 -- 100) | *100 (7/7) *7 (3 -- 21) | *81 (13/16) *6 (2 -- 57) |
Total | FD LDav | *78 (14/18) *4 (2 -- 26) | *88 (36/41) *6 (2 -- 94) | *44 (8/18) *4 (2 -- 7) | *85 (35/41) *9 (2 -- 100) | *64 (9/14) *6 (3 -- 21) | *68 (15/22) *6 (2 -- 57) |